Molecular and functional properties of densely and sparsely granulated GH-producing pituitary adenomas

European Journal of Endocrinology

Volumn 169, Issue 4, 2013, Pages 391-400

  Mayr, Bernhard ^a   Buslei, Rolf ^a   Theodoropoulou, Marily ^b   Stalla, Gunter K ^b   Buchfelder, Michael ^a   Schofl, Christof ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b MAX PLANCK INSTITUTE OF PSYCHIATRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CALCIUM CHANNEL; CALCIUM ION; CYCLIC AMP; GROWTH HORMONE; PROLACTIN; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR ZAC1; UNCLASSIFIED DRUG; VOLTAGE SENSITIVE CALCIUM CHANNEL;

ADULT; AGED; ARTICLE; CALCIUM CELL LEVEL; CALCIUM TRANSPORT; CELL MEMBRANE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOPLASM; DENSELY GRANULATED GROWTH HORMONE PRODUCING PITUITARY ADENOMA; FEMALE; GENE; GENE EXPRESSION; GENE MUTATION; GNAS1 GENE; GROWTH HORMONE SECRETING ADENOMA; GSP ONCOGENE; HUMAN; HUMAN CELL; HUMAN TISSUE; ICER GENE; INTRACELLULAR SIGNALING; MALE; ONCOGENE; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SOMATOSTATIN RECEPTOR 1 GENE; SOMATOSTATIN RECEPTOR 2 GENE; SOMATOSTATIN RECEPTOR 3 GENE; SOMATOSTATIN RECEPTOR 4 GENE; SOMATOSTATIN RECEPTOR 5 GENE; SPARSELY GRANULATED GROWTH HORMONE PRODUCING PITUITARY ADENOMA; UPREGULATION; ZAC1 GENE;

ACROMEGALY; ADENOMA; ADULT; ANTINEOPLASTIC AGENTS, HORMONAL; CALCIUM SIGNALING; CELL CYCLE PROTEINS; CYCLIC AMP; CYCLIC AMP RESPONSE ELEMENT MODULATOR; CYTOPLASMIC GRANULES; FEMALE; GENE EXPRESSION; GROWTH HORMONE-SECRETING PITUITARY ADENOMA; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; HUMANS; MALE; MIDDLE AGED; OCTREOTIDE; PRIMARY CELL CULTURE; RECEPTORS, SOMATOSTATIN; SECRETORY VESICLES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED; TUMOR SUPPRESSOR PROTEINS;

EID: 84884878045     PISSN: 08044643     EISSN: 1479683X     Source Type: Journal    
DOI: 10.1530/EJE-13-0134     Document Type: Article

References (60)

1. Asa SL & Ezzat S. The pathogenesis of pituitary tumours. Nature Reviews. Cancer 2002 2 836-849. (doi:10.1038/nrc926) (Pubitemid 37328902)
2. Drange MR & Melmed S. Molecular pathogenesis of acromegaly. Pituitary 1999 2 43-50. (doi:10.1023/A:1009917920589)
3. Karhu A & Aaltonen LA. Susceptibility to pituitary neoplasia related to MEN-1, CDKN1B and AIP mutations: an update. Human Molecular Genetics 2007 16 R73-R79. (doi:10.1093/hmg/ddm036) (Pubitemid 47241845)
4. Landis CA, Masters SB, Spada A, Pace AM, Bourne HR & Vallar L. GTPase inhibiting mutations activate the a chain of Gs and stimulate adenylyl cyclase in human pituitary tumours. Nature 1989 340 692-696. (doi:10.1038/340692a0) (Pubitemid 19214389)
5. Vierimaa O, Georgitsi M, Lehtonen R, Vahteristo P, Kokko A, Raitila A, Tuppurainen K, Ebeling TM, Salmela PI, Paschke R et al. Pituitary adenoma predisposition caused by germline mutations in the AIP gene. Science 2006 312 1228-1230. (doi:10.1126/science.1126100) (Pubitemid 43801151)
6. Leontiou CA, Gueorguiev M, van der Spuy J, Quinton R, Lolli F, Hassan S, Chahal HS, Igreja SC, Jordan S, Rowe J et al. The role of the aryl hydrocarbon receptor-interacting protein gene in familial and sporadic pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 2390-2401. (doi:10.1210/jc.2007-2611) (Pubitemid 351831563)
7. Horvath E & Kovacs K. Pathology of acromegaly. Neuroendocrinology 2006 83 161-165. (doi:10.1159/000095524) (Pubitemid 44578868)
8. Obari A, Sano T, Ohyama K, Kudo E, Qian ZR, Yoneda A, Rayhan N, Mustafizur Rahman M & Yamada S. Clinicopathological features of growth hormone-producing pituitary adenomas: difference among various types defined by cytokeratin distribution pattern including a transitional form. Endocrine Pathology 2008 19 82-91. (doi:10.1007/s12022-008-9029-z)
9. Bakhtiar Y, Hirano H, Arita K, Yunoue S, Fujio S, Tominaga A, Sakoguchi T, Sugiyama K, Kurisu K, Yasufuku-Takano J et al. Relationship between cytokeratin staining patterns and clinicopathological features in somatotropinomae. European Journal of Endocrinology 2010 163 531-539. (doi:10.1530/EJE-10-0586)
10. Bhayana S, Booth GL, Asa SL, Kovacs K & Ezzat S. The implication of somatotroph adenoma phenotype to somatostatin analog responsiveness in acromegaly. Journal of Clinical Endocrinology and Metabolism 2005 90 6290-6295. (doi:10.1210/jc.2005-0998) (Pubitemid 41606558)
11. Fougner SL, Casar-Borota O, Heck A, Berg JP & Bollerslev J. Adenoma granulation pattern correlates with clinical variables and effect of somatostatin analogue treatment in a large series of patients with acromegaly. Clinical Endocrinology 2012 76 96-102. (doi:10.1111/j.1365-2265.2011.04163.x)
12. Larkin S, Reddy R, Karavitaki N, Cudlip S, Wass J & Ansorge O. Granulation pattern, but not GSP or GHR mutation, is associated with clinical characteristics in somatostatin-naive patients with somatotroph adenomas. European Journal of Endocrinology 2013 168 491-499. (doi:10.1530/EJE-12-0864)
13. Brzana J, Yedinak CG, Gultekin SH, Delashaw JB & Fleseriu M. Growth hormone granulation pattern and somatostatin receptor subtype 2A correlate with postoperative somatostatin receptor ligand response in acromegaly: a large single center experience. Pituitary 2013. In press. (doi:10.1007/s11102-012- 0445-1)
14. Lania A, Mantovani G, Ferrante E, Zavanone LM, Locatelli M, Corbetta S, Beck-Peccoz P & Spada A. Gonadotropin-releasing hormone initiates multiple signaling pathways in human GH-secreting adenomas. Journal of Endocrinological Investigation 2004 27 328-333. (Pubitemid 38744611)
15. Boikos SA & Stratakis CA. Molecular genetics of the cAMPdependent protein kinase pathway and of sporadic pituitary tumorigenesis. Human Molecular Genetics 2007 16 R80-R87. (doi:10.1093/hmg/ddm019) (Pubitemid 47241846)
16. Sato T, Nakamura Y, Shiimura Y, Ohgusu H, Kangawa K & Kojima M. Structure, regulation and function of ghrelin. Journal of Biochemistry 2012 151 119-128. (doi:10.1093/jb/mvr134)
17. Lim CT, Kola B & Korbonits M. The ghrelin/GOAT/GHS-R system and energy metabolism. Reviews in Endocrine & Metabolic Disorders 2011 12 173-186. (doi:10.1007/s11154-011-9169-1)
18. Meier K, Knepel W & Schofl C. Potassium depolarization elevates cytosolic free calcium concentration in rat anterior pituitary cells through 1,4-dihydropyridine-sensitive, omega-conotoxin-insensitive calcium channels. Endocrinology 1988 122 2764-2770. (doi:10.1210/endo-122-6-2764)
19. Schofl C, Sandow J & KnepelW. GRF elevates cytosolic free calcium concentration in rat anterior pituitary cells. American Journal of Physiology 1987 253 E591-E594.
20. Garcia A, Alvarez CV, Smith RG & Dieguez C. Regulation of Pit-1 expression by ghrelin and GHRP-6 through the GH secretagogue receptor. Molecular Endocrinology 2001 15 1484-1495. (doi:10. 1210/me.15.9.1484) (Pubitemid 32826401)
21. Yamashita N, Shibuya N & Ogata E. Hyperpolarization of the membrane potential caused by somatostatin in dissociated human pituitary adenoma cells that secrete growth hormone. PNAS 1986 83 6198-6202. (doi:10.1073/pnas.83.16. 6198) (Pubitemid 16000680)
22. Yasufuku-Takano J, Takano K, Takei T, Fukumoto S, Teramoto A, Takakura K, Yamashita N & Fujita T. Heterozygous gsp mutation renders ion channels of human somatotroph adenoma cells unresponsive to growth hormone-releasing hormone. Endocrinology 1999 140 2018-2026. (doi:10.1210/en.140.5.2018) (Pubitemid 30636438)
23. Bilezikjian LM & Vale WW. Stimulation of adenosine 30,50-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology 1983 113 1726-1731. (doi:10.1210/endo-113-5-1726) (Pubitemid 13023813)
24. Spada A, Reza-Elahi F, Lania A, Gil-del-Alamo P, Bassetti M & Faglia G. Hypothalamic peptides modulate cytosolic free Ca2C levels and adenylyl cyclase activity in human nonfunctioning pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1991 73 913-918. (doi:10.1210/jcem-73-4-913) (Pubitemid 21921958)
25. Chen ZP, Xu S, Lightman SL, Hall L & Levy A. Intracellular calcium ion responses to somatostatin in cells from human somatotroph adenomas. Clinical Endocrinology 1997 46 45-53. (doi:10.1046/j.1365-2265.1997.d01-1739.x) (Pubitemid 27072845)
26. Theodoropoulou M, Zhang J, Laupheimer S, Paez-Pereda M, Erneux C, Florio T, Pagotto U & Stalla GK. Octreotide, a somatostatin analogue, mediates its antiproliferative action in pituitary tumor cells by altering phosphatidylinositol 3-kinase signaling and inducing Zac1 expression. Cancer Research 2006 66 1576-1582. (doi:10.1158/0008-5472.CAN-05-1189) (Pubitemid 43259940)
27. Pagotto U, Arzberger T, Theodoropoulou M, Gru bler Y, Pantaloni C, Saeger W, Losa M, Journot L, Stalla GK & Spengler D. The expression of the antiproliferative gene ZAC is lost or highly reduced in nonfunctioning pituitary adenomas. Cancer Research 2000 60 6794-6799. (Pubitemid 32059140)
28. Theodoropoulou M, Stalla GK & Spengler D. ZAC1 target genes and pituitary tumorigenesis. Molecular and Cellular Endocrinology 2010 326 60-65. (doi:10.1016/j.mce.2010.01.033)
29. Buslei R, Holsken A, Hofmann B, Kreutzer J, Siebzehnru bl F, Hans V, Oppel F, Buchfelder M, Fahlbusch R & Blumcke I. Nuclear b-catenin accumulation associates with epithelial morphogenesis in craniopharyngiomas. Acta Neuropathologica 2007 113 585-590. (doi:10.1007/s00401-006-0184-3) (Pubitemid 46672605)
30. Parry JJ, Chen R, Andrews R, Lears KA & Rogers BE. Identification of critical residues involved in ligand binding and G protein signaling in human somatostatin receptor subtype 2. Endocrinology 2012 153 2747-2755. (doi:10.1210/en.2011-1662)
31. Schmid HA, Lambertini C, van Vugt HH, Barzaghi-Rinaudo P, Schafer J, Hillenbrand R, Sailer AW, Kaufmann M & Nuciforo P. Monoclonal antibodies against the human somatostatin receptor subtypes 1-5: development and immunohistochemical application in neuroendocrine tumors. Neuroendocrinology 2012 95 232-247. (doi:10.1159/000330616)
32. Cordoba-Chacon J, Gahete MD, Duran-Prado M, Luque RM & Castano JP. Truncated somatostatin receptors as new players in somatostatin-cortistatin pathophysiology. Annals of the New York Academy of Sciences 2011 1220 6-15. (doi:10.1111/j.1749-6632.2011.05985.x)
33. Duran-Prado M, Gahete MD, Hergueta-Redondo M, Martinez-Fuentes AJ, Cordoba-Chacon J, Palacios J, Gracia-Navarro F, Moreno-Bueno G, Malagon MM, Luque RM et al. The new truncated somatostatin receptor variant sst5TMD4 is associated to poor prognosis in breast cancer and increases malignancy in MCF-7 cells. Oncogene 2012 31 2049-2061. (doi:10.1038/onc. 2011.389)
34. Plockinger U, Albrecht S, Mawrin C, Saeger W, Buchfelder M, Petersenn S & Schulz S. Selective loss of somatostatin receptor 2 in octreotide-resistant growth hormone-secreting adenomas. Journal of Clinical Endocrinology and Metabolism 2008 93 1203-1210. (doi:10.1210/jc.2007-1986) (Pubitemid 351519711)
35. Kulaksiz H, Eissele R, Rossler D, Schulz S, Hollt V, Cetin Y & Arnold R. Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies. Gut 2002 50 52-60. (doi:10.1136/gut.50.1.52) (Pubitemid 34028303)
36. Kumar U, Sasi R, Suresh S, Patel A, Thangaraju M, Metrakos P, Patel SC & Patel YC. Subtype-selective expression of the five somatostatin receptors (hSSTR1-5) in human pancreatic islet cells: a quantitative double-label immunohistochemical analysis. Diabetes 1999 48 77-85. (doi:10.2337/diabetes.48. 1.77) (Pubitemid 29019355)
37. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C et al. Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Modern Pathology 2007 20 1172-1182. (doi:10.1038/modpathol.3800954) (Pubitemid 47609066)
38. Unger N, Serdiuk I, Sheu SY, Walz MK, Schulz S, Saeger W, Schmid KW, Mann K & Petersenn S. Immunohistochemical localization of somatostatin receptor subtypes in benign and malignant adrenal tumours. Clinical Endocrinology 2008 68 850-857. (doi:10.1111/j.1365-2265.2007.03124.x) (Pubitemid 351703940)
39. Rus R, Haag C, Bumke-Vogt C, Bahr V, Mayr B, Mohlig M, Schulze E, Frank-Raue K, Raue F & Schofl C. Novel inactivating mutations of the calcium-sensing receptor: the calcimimetic NPS R-568 improves signal transduction of mutant receptors. Journal of Clinical Endocrinology and Metabolism 2008 93 4797-4803. (doi:10.1210/jc.2008-1076)
40. Mayr BM, Canettieri G & Montminy MR. Distinct effects of cAMP and mitogenic signals on CREB-binding protein recruitment impart specificity to target gene activation via CREB. PNAS 2001 98 10936-10941. (doi:10.1073/pnas. 191152098) (Pubitemid 32878722)
41. Taboada GF, Luque RM, Bastos W, Guimaraes RF, Marcondes JB, Chimelli LM, Fontes R, Mata PJ, Filho PN, Carvalho DP et al. Quantitative analysis of somatostatin receptor subtype (SSTR1-5) gene expression levels in somatotropinomas and non-functioning pituitary adenomas. European Journal of Endocrinology 2007 156 65-74. (doi:10.1530/eje.1.02313) (Pubitemid 46553904)
42. Tichopad A, Dilger M, Schwarz G & Pfaffl MW. Standardized determination of real-time PCR efficiency from a single reaction set-up. Nucleic Acids Research 2003 31 e122. (doi:10.1093/nar/gng122)
43. Mayr B & Montminy M. Transcriptional regulation by the phosphorylation-dependent factor CREB. Nature Reviews. Molecular Cell Biology 2001 2 599-609. (doi:10.1038/35085068) (Pubitemid 33674011)
44. Holl RW, Thorner MO, Mandell GL, Sullivan JA, Sinha YN & Leong DA. Spontaneous oscillations of intracellular calcium and growth hormone secretion. Journal of Biological Chemistry 1988 263 9682-9685.
45. Miller GM, Alexander JM, Bikkal HA, Katznelson L, Zervas NT & Klibanski A. Somatostatin receptor subtype gene expression in pituitary adenomas. Journal of Clinical Endocrinology and Metabolism 1995 80 1386-1392. (doi:10.1210/jc.80.4.1386)
46. Pisarek H, Krupinski R, Kubiak R, Borkowska E, Pawlikowski M & Winczyk K. Differential expression of somatostatin receptor subtype-related genes and proteins in non-functioning and functioning adrenal cortex adenomas. Molecular Medicine Reports 2011 4 963-969.
47. Kumar U, Grigorakis SI, Watt HL, Sasi R, Snell L, Watson P & Chaudhari S. Somatostatin receptors in primary human breast cancer: quantitative analysis of mRNA for subtypes 1-5 and correlation with receptor protein expression and tumor pathology. Breast Cancer Research and Treatment 2005 92 175-186. (doi:10.1007/s10549-005-2414-0) (Pubitemid 40933583)
48. Pisarek H, Stepien T, Kubiak R, Borkowska E & Pawlikowski M. Expression of somatostatin receptor subtypes in human thyroid tumors: the immunohistochemical and molecular biology (RT-PCR) investigation. Thyroid Research 2009 2 1. (doi:10.1186/1756-6614-2-1)
49. Oriolo AS, Wald FA, Ramsauer VP & Salas PJ. Intermediate filaments: a role in epithelial polarity. Experimental Cell Research 2007 313 2255-2264. (doi:10.1016/j.yexcr.2007.02.030) (Pubitemid 46842972)
50. Shimon I, Taylor JE, Dong JZ, Bitonte RA, Kim S, Morgan B, Coy DH, Culler MD & Melmed S. Somatostatin receptor subtype specificity in human fetal pituitary cultures. Differential role of SSTR2 and SSTR5 for growth hormone, thyroid-stimulating hormone, and prolactin regulation. Journal of Clinical Investigation 1997 99 789-798. (doi:10.1172/JCI119225)
51. Shimon I, Yan X, Taylor JE, Weiss MH, Culler MD & Melmed S. Somatostatin receptor (SSTR) subtype-selective analogues differentially suppress in vitro growth hormone and prolactin in human pituitary adenomas. Novel potential therapy for functional pituitary tumors. Journal of Clinical Investigation 1997 100 2386-2392. (doi:10.1172/JCI119779) (Pubitemid 27500164)
52. Olias G, Viollet C, Kusserow H, Epelbaum J & Meyerhof W. Regulation and function of somatostatin receptors. Journal of Neurochemistry 2004 89 1057-1091. (doi:10.1111/j.1471-4159.2004.02402.x) (Pubitemid 38720193)
53. Barlier A, Pellegrini-Bouiller I, Gunz G, Zamora AJ, Jaquet P & Enjalbert A. Impact of gsp oncogene on the expression of genes coding for Gsa, Pit-1, Gi2a, and somatostatin receptor 2 in human somatotroph adenomas: involvement in octreotide sensitivity. Journal of Clinical Endocrinology and Metabolism 1999 84 2759-2765. (doi:10.1210/jc.84.8.2759) (Pubitemid 30642008)
54. Jaquet P, Saveanu A, Gunz G, Fina F, Zamora AJ, Grino M, Culler MD, Moreau JP, Enjalbert A & Ouafik LH. Human somatostatin receptor subtypes in acromegaly: distinct patterns of messenger ribonucleic acid expression and hormone suppression identify different tumoral phenotypes. Journal of Clinical Endocrinology and Metabolism 2000 85 781-792. (doi:10.1210/jc.85.2.781) (Pubitemid 32273669)
55. Ferone D, de HerderWW, Pivonello R, Kros JM, van Koetsveld PM, de Jong T, Minuto F, Colao A, Lamberts SW & Hofland LJ. Correlation of in vitro and in vivo somatotropic adenoma responsiveness to somatostatin analogs and dopamine agonists with immunohistochemical evaluation of somatostatin and dopamine receptors and electron microscopy. Journal of Clinical Endocrinology and Metabolism 2008 93 1412-1417. (doi:10.1210/jc.2007-1358) (Pubitemid 351522738)
56. Fougner SL, Borota OC, Berg JP, Hald JK, Ramm-Pettersen J & Bollerslev J. The clinical response to somatostatin analogues in acromegaly correlates to the somatostatin receptor subtype 2a protein expression of the adenoma. Clinical Endocrinology 2008 68 458-465. (doi:10.1111/j.1365-2265.2007. 03065.x) (Pubitemid 351257867)
57. Lancranjan I, Bruns C, Grass P, Jaquet P, Jervell J, Kendall-Taylor P, Lamberts SWJ, Marbach P, Ørskov H, Pagani G et al. Sandostatin LARw: pharmacokinetics, pharmacodynamics, efficacy, and tolerability in acromegalic patients. Metabolism 1995 44 (Suppl 1) 18-26. (doi:10.1016/0026-0495(95)90306-2)
58. Petersenn S, Farrall AJ, Block C, Melmed S, Schopohl J, Caron P, Cuneo R, Kleinberg D, Colao A, Ruffin M et al. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, phase II extension study. Pituitary 2013. In press. (doi:10.1007/s11102-013- 0478-0)
59. Petersenn S, Schopohl J, Barkan A, Mohideen P, Colao A, Abs R, Buchelt A, Ho YY, Hu K, Farrall AJ et al. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial. Journal of Clinical Endocrinology and Metabolism 2010 95 2781-2789. (doi:10. 1210/jc.2009-2272)
60. Hofland LJ, van der Hoek J, van Koetsveld PM, de Herder WW, Waaijers M, Sprij-Mooij D, Bruns C, Weckbecker G, Feelders R, van der Lely AJ et al. The novel somatostatin analog SOM230 is a potent inhibitor of hormone release by growth hormoneand prolactin-secreting pituitary adenomas in vitro. Journal of Clinical Endocrinology and Metabolism 2004 89 1577-1585. (doi:10.1210/jc.2003- 031344) (Pubitemid 38507905)